{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T15:14:19Z","timestamp":1791126859041,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","ijaaonline.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.ijantimicag.2018.08.001","type":"journal-article","created":{"date-parts":[[2018,8,10]],"date-time":"2018-08-10T16:32:02Z","timestamp":1533918722000},"page":"643-650","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Comparative incidence and excess risk of acute kidney injury in hospitalised patients receiving vancomycin and piperacillin\/tazobactam in combination or as monotherapy"],"prefix":"10.1016","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9272-6973","authenticated-orcid":false,"given":"Joseph","family":"Carreno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tori","family":"Smiraglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellis","family":"Tobin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Lomaestro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2018.08.001_bib0001","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1001\/jama.2014.12923","article-title":"Prevalence of antimicrobial use in US acute care hospitals, May\u2013September 2011","volume":"312","author":"Magill","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.ijantimicag.2018.08.001_bib0002","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1001\/jamainternmed.2016.5651","article-title":"Estimating national trends in inpatient antibiotic use among US hospitals from 2006 to 2012","volume":"176","author":"Baggs","year":"2016","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.ijantimicag.2018.08.001_bib0003","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1002\/phar.1488","article-title":"Vancomycin-associated renal dysfunction: where are we now?","volume":"34","author":"Carreno","year":"2014","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2018.08.001_bib0004","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1086\/600877","article-title":"Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists","volume":"49","author":"Rybak","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.08.001_bib0005","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1086\/600884","article-title":"Relationship between initial vancomycin concentration\u2013time profile and nephrotoxicity among hospitalized patients","volume":"49","author":"Lodise","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.08.001_bib0006","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1128\/AAC.01602-07","article-title":"Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity","volume":"52","author":"Lodise","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.08.001_bib0007","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1128\/AAC.00173-11","article-title":"Applying new diagnostic criteria for acute kidney injury to facilitate early identification of nephrotoxicity in vancomycin-treated patients","volume":"55","author":"Minejima","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.08.001_bib0008","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/2050-6511-14-12","article-title":"Empiric guideline-recommended weight-based vancomycin dosing and nephrotoxicity rates in patients with methicillin-resistant Staphylococcus aureus bacteremia: a retrospective cohort study","volume":"14","author":"Hall","year":"2013","journal-title":"BMC Pharmacol Toxicol"},{"key":"10.1016\/j.ijantimicag.2018.08.001_bib0009","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1128\/AAC.01568-12","article-title":"Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter","volume":"57","author":"van Hal","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.08.001_bib0010","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.clinthera.2011.12.013","article-title":"Incidence of nephrotoxicity and association with vancomycin use in intensive care unit patients with pneumonia: retrospective analysis of the IMPACT-HAP Database","volume":"34","author":"Cano","year":"2012","journal-title":"Clin Ther"},{"key":"10.1016\/j.ijantimicag.2018.08.001_bib0011","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.clinthera.2007.06.014","article-title":"A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia","volume":"29","author":"Jeffres","year":"2007","journal-title":"Clin Ther"},{"key":"10.1016\/j.ijantimicag.2018.08.001_bib0012","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1086\/597031","article-title":"Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic","volume":"48","author":"Cosgrove","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.08.001_bib0013","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1093\/jac\/33.4.811","article-title":"A comparative assessment of vancomycin-associated nephrotoxicity in the young versus the elderly hospitalized patient","volume":"33","author":"Vance-Bryan","year":"1994","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2018.08.001_bib0014","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s40261-013-0163-0","article-title":"Risk factors for acute kidney injury in adult patients receiving vancomycin","volume":"34","author":"Cappelletty","year":"2014","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.ijantimicag.2018.08.001_bib0015","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1016\/j.rmed.2006.01.004","article-title":"Comparison of piperacillin\/tazobactam and imipenem\/cilastatin, both in combination with tobramycin, administered every 6 h for treatment of nosocomial pneumonia","volume":"100","author":"Joshi","year":"2006","journal-title":"Respir Med"},{"key":"10.1016\/j.ijantimicag.2018.08.001_bib0016","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1053\/j.ackd.2016.11.004","article-title":"Mechanisms of drug-induced interstitial nephritis","volume":"24","author":"Raghavan","year":"2017","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.ijantimicag.2018.08.001_bib0017","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/cid\/ciw811","article-title":"Systematic review and meta-analysis of acute kidney injury associated with concomitant vancomycin and piperacillin\/tazobactam","volume":"64","author":"Hammond","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.08.001_bib0018","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1099\/jmm.0.000211","article-title":"Effect of piperacillin\/tazobactam restriction on usage and rates of acute renal failure","volume":"65","author":"Lorenz","year":"2016","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.ijantimicag.2018.08.001_bib0019","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/CCM.0000000000002769","article-title":"Vancomycin plus piperacillin\u2013tazobactam and acute kidney injury in adults: a systematic review and meta-analysis","volume":"46","author":"Luther","year":"2018","journal-title":"Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2018.08.001_bib0020","doi-asserted-by":"crossref","first-page":"77","DOI":"10.12788\/jhm.2684","article-title":"Acute kidney injury in patients treated with vancomycin and piperacillin\u2013tazobactam: a retrospective cohort analysis","volume":"12","author":"Rutter","year":"2017","journal-title":"J Hosp Med"},{"key":"10.1016\/j.ijantimicag.2018.08.001_bib0021","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/phar.1851","article-title":"Is the combination of piperacillin\u2013tazobactam and vancomycin associated with development of acute kidney injury? A meta-analysis","volume":"36","author":"Giuliano","year":"2016","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2018.08.001_bib0022","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/1060028016673858","article-title":"Randomized controlled trial to determine the efficacy of early switch from vancomycin to vancomycin alternatives as a strategy to prevent nephrotoxicity in patients with multiple risk factors for adverse renal outcomes (STOP-NT)","volume":"51","author":"Carreno","year":"2017","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ijantimicag.2018.08.001_bib0023","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s40121-013-0022-6","article-title":"Comparative incidence of nephrotoxicity by age group among adult patients receiving vancomycin","volume":"2","author":"Carreno","year":"2013","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.ijantimicag.2018.08.001_bib0024","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1186\/cc5713","article-title":"Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury","volume":"11","author":"Mehta","year":"2007","journal-title":"Crit Care"},{"key":"10.1016\/j.ijantimicag.2018.08.001_bib0025","series-title":"Modern epidemiology","author":"Rothman","year":"2008"},{"key":"10.1016\/j.ijantimicag.2018.08.001_bib0026","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"key":"10.1016\/j.ijantimicag.2018.08.001_bib0027","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2307\/2529781","article-title":"Sample size determinants for r X c comparative trials","volume":"33","author":"Lachin","year":"1977","journal-title":"Biometrics"},{"key":"10.1016\/j.ijantimicag.2018.08.001_bib0028","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1128\/AAC.03011-15","article-title":"Epidemiology of acute kidney injury among patients receiving concomitant vancomycin and piperacillin\u2013tazobactam: opportunities for antimicrobial stewardship","volume":"60","author":"Karino","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.08.001_bib0029","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/phar.1423","article-title":"Vancomycin-associated nephrotoxicity in adult medicine patients: incidence, outcomes, and risk factors","volume":"34","author":"Meaney","year":"2014","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2018.08.001_bib0030","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/phar.1428","article-title":"Comparison of acute kidney injury during treatment with vancomycin in combination with piperacillin\u2013tazobactam or cefepime","volume":"34","author":"Gomes","year":"2014","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2018.08.001_bib0031","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/phar.1442","article-title":"Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized patients with and without concomitant piperacillin\u2013tazobactam","volume":"34","author":"Burgess","year":"2014","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2018.08.001_bib0032","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1089\/sur.2015.104","article-title":"Top guns: the 'Maverick' and 'Goose' of empiric therapy","volume":"17","author":"Davies","year":"2016","journal-title":"Surg Infect (Larchmt)"},{"key":"10.1016\/j.ijantimicag.2018.08.001_bib0033","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/phar.1738","article-title":"Comparative incidence of acute kidney injury in critically ill patients receiving vancomycin with concomitant piperacillin\u2013tazobactam or cefepime: a retrospective cohort study","volume":"36","author":"Hammond","year":"2016","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2018.08.001_bib0034","series-title":"Society of Critical Care Medicine 41st Critical Care Congress","first-page":"4","article-title":"301: Retrospective evaluation of the incidence of vancomycin and\/or piperacillin\u2013tazobactam induced acute renal failure","author":"Hellwig","year":"2012"},{"key":"10.1016\/j.ijantimicag.2018.08.001_bib0035","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.clinthera.2016.01.001","article-title":"Impact of an antimicrobial stewardship program on patient safety in veterans prescribed vancomycin","volume":"38","author":"Fodero","year":"2016","journal-title":"Clin Ther"},{"key":"10.1016\/j.ijantimicag.2018.08.001_bib0036","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1186\/s13104-015-1518-9","article-title":"Risk factors for kidney injury during vancomycin and piperacillin\/tazobactam administration, including increased odds of injury with combination therapy","volume":"8","author":"Kim","year":"2015","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.ijantimicag.2018.08.001_bib0037","doi-asserted-by":"crossref","first-page":"5470","DOI":"10.1128\/AAC.00388-15","article-title":"Nephrotoxicity comparison of two commercially available generic vancomycin products","volume":"59","author":"Sutton","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.08.001_bib0038","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.jiph.2016.11.007","article-title":"Comparison of the incidence of acute kidney injury during treatment with vancomycin in combination with piperacillin\u2013tazobactam or with meropenem","volume":"10","author":"Al Yami","year":"2017","journal-title":"J Infect Public Health"},{"key":"10.1016\/j.ijantimicag.2018.08.001_bib0039","doi-asserted-by":"crossref","first-page":"O384","DOI":"10.1111\/1469-0691.12410","article-title":"Acute renal failure associated with vancomycin and \u03b2-lactams for the treatment of osteomyelitis in diabetics: piperacillin\u2013tazobactam as compared with cefepime","volume":"20","author":"Moenster","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2018.08.001_bib0040","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/cid\/ciw709","article-title":"Risk of acute kidney injury in patients on concomitant vancomycin and piperacillin\u2013tazobactam compared to those on vancomycin and cefepime","volume":"64","author":"Navalkele","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.08.001_bib0041","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1002\/phar.1847","article-title":"Antimicrobial monotherapy versus combination therapy for the treatment of complicated intra-abdominal infections","volume":"36","author":"Petite","year":"2016","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2018.08.001_bib0042","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1093\/cid\/cix675","article-title":"Increasing evidence of the nephrotoxicity of piperacillin\/tazobactam and vancomycin combination therapy\u2014what is the clinician to do?","volume":"65","author":"Watkins","year":"2017","journal-title":"Clin Infect Dis"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857918302279?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857918302279?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T08:57:29Z","timestamp":1751792249000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857918302279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S0924857918302279"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.08.001","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative incidence and excess risk of acute kidney injury in hospitalised patients receiving vancomycin and piperacillin\/tazobactam in combination or as monotherapy","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}